Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Unanswered questions regarding treatment cessation in CML

Francois-Xavier Mahon • 26 Nov 2021
ASH 2021
Chronic Myeloid Leukemia Leukemia

Francois-Xavier Mahon, MD, PhD, University of Bordeaux, Bordeaux, France, highlights unanswered questions regarding treatment discontinuation for patients with chronic myeloid leukemia (CML). Prof. Mahon notes that the mechanisms underlying late molecular recurrence are unclear and likely differ from those responsible for early recurrence in CML. Further research is needed to understand these processes and enable more accurate decision making regarding the feasibility of stopping treatment in an individual patient. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

More from Francois-Xavier Mahon

2:18
Recommendations for treatment discontinuation in CML
Francois-Xavier Mahon • 22 Oct 2022
0:54
Design & aims of the EURO-SKI trial in CML
Francois-Xavier Mahon • 22 Oct 2022
1:24
Key challenges in CML: QoL, managing CML in resource-challenged countries & achieving a cure
Francois-Xavier Mahon • 22 Oct 2022
1:05
Feasibility of treatment cessation in patients with CML with atypical BCR-ABL fusion transcripts
Francois-Xavier Mahon • 26 Nov 2021

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals